Loading articles...
Air Embolism: Two Cases After Percutaneous Lung Biopsy
Two cases highlight the rare but severe complication of air embolism following percutaneous lung biopsy, necessitating prompt recognition and management.
Dupilumab Superior to Omalizumab in High-Biomarker Asthma
Dupilumab demonstrated superior efficacy compared to omalizumab in patients with high-biomarker severe asthma, particularly regarding exacerbation rates and lung function.
Epithelial Cytokines Link Severe Asthma, CRSwNP, COPD at ATS 2026
ATS 2026 highlighted epithelial cytokine pathways as a common link in severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and COPD.
Triple Therapy in Asthma: Real-World Evidence Supports Earlier Use
New real-world evidence presented at ATS 2026 indicates that initiating triple therapy earlier in asthma management may improve patient outcomes.
Epithelial Dysfunction: A Unified Target in Airway Disease Management
ATS 2026 highlights epithelial dysfunction as a central mechanism in upper and lower airway inflammation, informing evolving management strategies.
AIRSUPRA® Reduces Asthma Exacerbations in ATS 2026 Data
AIRSUPRA® (albuterol/budesonide) demonstrated a reduction in asthma exacerbations, addressing the need for improved rescue therapy.
Severe Asthma: Beyond Airway Focus in Treatment Decisions at ATS 2026
ATS 2026 discussions on severe asthma treatment highlight the need to integrate patient-reported outcomes beyond lung function, addressing quality of life.
JASCAYD® (nerandomilast) Offers New Therapeutic Option for COPD
Nerandomilast, a novel anti-inflammatory agent, demonstrates efficacy in reducing exacerbation rates in patients with moderate to severe COPD.
New Biologic Offers Option for Severe Eosinophilic Asthma
A new biologic agent presented at ATS 2026 provides an additional treatment option for patients with severe eosinophilic asthma.
Dupilumab in Severe Asthma: Real-World Cohort Data Begin to Arrive
Three new studies examine dupilumab and biologic therapy in severe type 2 asthma, adding real-world weight to existing trial evidence.